Duloxetine
Brand names: Cymbalta, Yentreve
Duloxetine is a serotonin and noradrenaline reuptake inhibitor (SNRI) used for major depression, generalised anxiety disorder, diabetic peripheral neuropathic pain and, in some products, stress urinary incontinence.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits the reuptake of serotonin and noradrenaline in the central nervous system, enhancing descending inhibitory pain pathways and modulating mood and anxiety circuits.
Prescribing in practice
- It can raise blood pressure and should not be started in uncontrolled hypertension; monitor blood pressure, and avoid combination with other serotonergic drugs or recent monoamine oxidase inhibitor use because of serotonin syndrome risk.
- Avoid in significant hepatic impairment and in severe renal impairment, and stop gradually to reduce discontinuation symptoms.
- Monitor for suicidal ideation, particularly in younger adults and early in treatment, and counsel on increased bleeding risk when combined with antiplatelets or anticoagulants.
Monitoring
Monitor mood and suicidality, blood pressure, hepatic function if symptoms arise, and for serotonergic or bleeding adverse effects.
Counselling the patient
- Do not stop suddenly, as this can cause dizziness, electric-shock sensations and mood changes.
- Report worsening mood or thoughts of self-harm, especially in the first weeks.
- Seek urgent advice for agitation, fever, tremor or confusion suggesting serotonin toxicity.
Evidence & guidelines
Regulatory and NICE depression and neuropathic pain guidance support duloxetine as an established treatment option in its licensed indications.
Reference: NICE NG59 (Neuropathic Pain); NICE CG90 (Depression); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185